Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force
- PMID: 27064573
- DOI: 10.7326/M15-2129
Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force
Abstract
Background: Evidence indicates that aspirin is effective for the primary prevention of cardiovascular disease (CVD) and colorectal cancer (CRC) but also increases the risk for gastrointestinal (GI) and cerebral hemorrhages.
Objective: To assess the net balance of benefits and harms from routine aspirin use across clinically relevant age, sex, and CVD risk groups.
Design: Decision analysis using a microsimulation model.
Data sources: 3 systematic evidence reviews.
Target population: Men and women aged 40 to 79 years with a 10-year CVD risk of 20% or less, and no history of CVD and without elevated risk for GI or cerebral hemorrhages that would contraindicate aspirin use.
Time horizon: Lifetime, 20 years, and 10 years.
Perspective: Clinical.
Intervention: Low-dose aspirin (≤100 mg/d).
Outcome measures: Primary outcomes are length and quality of life measured in net life-years and quality-adjusted life-years. Benefits include reduced nonfatal myocardial infarction, nonfatal ischemic stroke, fatal CVD, CRC incidence, and CRC mortality. Harms include increased fatal and nonfatal GI bleeding and hemorrhagic stroke.
Results of base-case analysis: Lifetime net quality-adjusted life-years are positive for most adults initiating aspirin at ages 40 to 69 years, and life expectancy gains are expected for most men and women initiating aspirin at ages 40 to 59 years and 60 to 69 years with higher CVD risk. Harms may exceed benefits for persons starting aspirin in their 70s and for many during the first 10 to 20 years of use.
Results of sensitivity analysis: Results are most sensitive to the relative risk for hemorrhagic stroke and CVD mortality but are affected by all relative risk estimates, baseline GI bleeding incidence and case-fatality rates, and disutilities associated with aspirin use.
Limitations: Aspirin effects by age are uncertain. Stroke benefits are conservatively estimated. Gastrointestinal bleeding incidence and case-fatality rates account only for age and sex.
Conclusion: Lifetime aspirin use for primary prevention initiated at younger ages (40 to 69 years) and in persons with higher CVD risk shows the greatest potential for positive net benefit.
Primary funding source: Agency for Healthcare Research and Quality.
Similar articles
-
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: An Updated Decision Analysis for the U.S. Preventive Services Task Force [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Apr. Report No.: 21-05283-EF-2. Rockville (MD): Agency for Healthcare Research and Quality (US); 2022 Apr. Report No.: 21-05283-EF-2. PMID: 35648884 Free Books & Documents. Review.
-
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Updated Modeling Study for the US Preventive Services Task Force.JAMA. 2022 Apr 26;327(16):1598-1607. doi: 10.1001/jama.2022.3385. JAMA. 2022. PMID: 35471506
-
Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.Ann Intern Med. 2016 Jun 21;164(12):836-45. doi: 10.7326/M16-0577. Epub 2016 Apr 12. Ann Intern Med. 2016. PMID: 27064677
-
Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.Ann Intern Med. 2016 Jun 21;164(12):826-35. doi: 10.7326/M15-2112. Epub 2016 Apr 12. Ann Intern Med. 2016. PMID: 27064261 Review.
-
Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: A Decision Analysis: Technical Report [Internet].Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. Report No.: 15-05229-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep. Report No.: 15-05229-EF-1. PMID: 26491755 Free Books & Documents. Review.
Cited by
-
Scoping review of interventions to de-implement potentially harmful non-steroidal anti-inflammatory drugs (NSAIDs) in healthcare settings.BMJ Open. 2024 Apr 17;14(4):e078808. doi: 10.1136/bmjopen-2023-078808. BMJ Open. 2024. PMID: 38631836 Free PMC article. Review.
-
Identifying and reducing inappropriate aspirin use in primary care.BMJ Open Qual. 2023 Nov;12(4):e002457. doi: 10.1136/bmjoq-2023-002457. BMJ Open Qual. 2023. PMID: 37931985 Free PMC article.
-
Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats.Molecules. 2023 Feb 15;28(4):1844. doi: 10.3390/molecules28041844. Molecules. 2023. PMID: 36838830 Free PMC article.
-
Phenolic Phytochemicals for Prevention and Treatment of Colorectal Cancer: A Critical Evaluation of In Vivo Studies.Cancers (Basel). 2023 Feb 3;15(3):993. doi: 10.3390/cancers15030993. Cancers (Basel). 2023. PMID: 36765950 Free PMC article. Review.
-
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer's disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies.Alzheimers Res Ther. 2022 May 28;14(1):75. doi: 10.1186/s13195-022-01017-4. Alzheimers Res Ther. 2022. PMID: 35624487 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials